Takeda opens 4th front in assault on celiac, tapping Innate to develop antibody-drug conjugates

Takeda really wants to land a hit on celiac disease. Not content with having just three pipeline prospects, the Japanese drugmaker has partnered with Innate Pharma to attack the disease with another modality: antibody-drug conjugates (ADCs).